Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

theramex ireland limited - teriparatidi - osteoporoosi - kalsiumin homeostaasi - livogiva is indicated in adults. osteoporoosin hoito postmenopausaalisilla naisilla ja miehillä, joilla on lisääntynyt murtumisriski. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. hoito osteoporoosi liittyy pitkäaikaiseen, systeemiseen glukokortikoidihoitoon naisilla ja miehillä on suurempi riski saada murtuma.

Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatidi - osteoporoosi - kalsiumin homeostaasi - sondelbay is indicated in adults. osteoporoosin hoito postmenopausaalisilla naisilla ja miehillä, joilla on lisääntynyt murtumisriski. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. hoito osteoporoosi liittyy pitkäaikaiseen, systeemiseen glukokortikoidihoitoon naisilla ja miehillä on suurempi riski saada murtuma.

Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatidi - osteoporosis; osteoporosis, postmenopausal - kalsiumin homeostaasi - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Unjoni Ewropea - Finlandiż - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatidi - osteoporosis; osteoporosis, postmenopausal - kalsiumin homeostaasi - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

boehringer ingelheim international gmbh - dipyridamolum - tabletti, päällystetty - 25 mg - dipyridamoli

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

boehringer ingelheim international gmbh - dipyridamolum - tabletti, päällystetty - 100 mg - dipyridamoli

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

primex pharmaceuticals oy - propofol - injektio/infuusioneste, emulsio - 10 mg/ml - propofoli

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

primex pharmaceuticals oy - propofol - injektio/infuusioneste, emulsio - 20 mg/ml - propofoli

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

jazz pharmaceuticals ireland limited - delta-9-tetrahydrocannabinol, cannabidiol, cannabis extract - sumute suuonteloon, liuos - kannabinoidit

Finlandja - Finlandiż - Fimea (Suomen lääkevirasto)

essential pharma (m) ltd - calcitonin, salmon - injektio/infuusioneste, liuos - 100 iu/ml - kalsitoniini (lohen synteettinen)